IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Zacks News
Medtronic (MDT) Progresses in SNM With Updated InterStim Label
by Zacks Equity Research
Medtronic (MDT) expects this updated labeling with wider procedural options and shorter wait time to improve patient access to MRI exams and add more flexibility for MRI providers.
Globus Medical (GMED) Q4 Earnings Beat, U.S. Business Strong
by Zacks Equity Research
Globus Medical's (GMED) spinal implant business performance varies by region in Q4.
Ecolab's (ECL) Certified Program to Build Customer Confidence
by Zacks Equity Research
Ecolab's (ECL) science-backed comprehensive program to help food retailers to support customer confidence.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Henry Schein (HSIC) sees robust segmental performance in Q4 boosted by strong rebound in sales, and solid demand for PPE and COVID-19-related products.
Exact Sciences (EXAS) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business sees an uptick in revenues in Q4 earnings.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.
NEOGEN's (NEOG) New Test to Identify Coronavirus in Wastewater
by Zacks Equity Research
Launch of NEOGEN's (NEOG) latest test, which marks its entry into wastewater testing, is expected to become a key tool to combat COVID-19.
CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y
by Zacks Equity Research
The pandemic affects CVS Health's (CVS) fourth-quarter revenues in the Pharmacy Services segments as new therapy prescriptions reduce due to lower provider visits.
TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows
by Zacks Equity Research
TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.
Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.
by Zacks Equity Research
Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.
Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.
Medtronic's (MDT) Nellcor Favored in Study Over Masimo's Oximetry
by Zacks Equity Research
Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.
New Study Favors Myriad Genetics' (MYGN) GeneSight Test
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight Psychotropic test is better for predicting patient outcomes and medication blood levels than single-gene testing, per new study.
QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.
Cardiovascular Systems (CSII) Posts Break-Even Earnings in Q2
by Zacks Equity Research
Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.
Align Technology (ALGN) Beats on Q4 Earnings, Margins Up
by Zacks Equity Research
Align Technology's (ALGN) segments report solid sales across geographies despite the pandemic-led business challenges.
The Cooper Companies (COO) Unit Gets a Boost From New Buyout
by Zacks Equity Research
The Cooper Companies (COO) arm's buyout drives its growing portfolio of medical products, which revolves around clinic and practice-based women's healthcare
IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise
by Zacks Equity Research
IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.
Why You Should Add AngioDynamics (ANGO) to Your Portfolio
by Zacks Equity Research
Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.
Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 40.56% and 5.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Segments
by Zacks Equity Research
Thermo Fisher (TMO) records $3.2 billion of COVID-19 response revenues and accelerated growth in base business in Q4.
MedTech Stock Earnings on Feb 2: IDXX, MCK & More
by Urmimala Biswas
In Q4, MedTech stocks are expected to have gained from month-wise sales rebound in many states and regions. However, international sales might have been dampened.
NextGen Healthcare (NXGN) Loses 8.8% Despite Q3 Earnings Beat
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strong segmental performance.
Accuray (ARAY) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Accuray (ARAY) registers growth in Service revenues during fiscal Q2.